Phase III TAGS data for Lonsurf consistent with earlier studies in gastric cancer.- Taiho Oncology + Servier

Taiho Oncology and Servier announced that the safety and efficacy in patients with gastrectomy from the global Phase III TAGS trial evaluating Lonsurf (trifluridine + tipiracil) in patients with previously treated metastatic gastric cancer (mGC) are consistent with the overall study results published in The Lancet Oncology.

In the TAGS trial, 221 (44%) of the 507 randomized mGC patients had undergone prior gastrectomy (147 Lonsurf, 74 placebo), which is reflective of the real-world patient population diagnosed with mGC. The results confirmed that Lonsurf prolonged survival versus placebo regardless of prior gastrectomy. These data were highlighted at the ASCO 2019 Gastrointestinal Cancers Symposium.

Comment: Lonsurf is indicated in the United States for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy and, if RAS wild-type, an anti-EGFR therapy.

See- "Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase III trial." Kohei Shitara et al. The Lancet Oncology October 21, 2018DOI:https://doi.org/10.1016/S1470-2045(18)30739-3